20/20 Onsite

Home
United States
Boston, MA
20/20 Onsite

20/20 Onsite delivers comprehensive eye exams to businesses via a state-of-art mobile vision center.

20/20 Onsite (also known as 2020 Onsite) is the only provider solely dedicated to point-of-need eye assessments for clinical trials, proven to meet screening timelines, improve retention rates, and fast-track trials. This is a great way for companies to offer a unique, low-cost benefit to employees.

09/03/2026

What happens when required post-market safety exams become a barrier to clinical trial patients receiving treatment?

For pediatric patients with cystic fibrosis (CF), access to ophthalmic care can be especially challenging. Long appointment wait times, rural access barriers, and concerns for immunocompromised patients can all delay necessary safety assessments.

20/20 Onsite partnered with a large biopharmaceutical company to bring post-market ophthalmic assessments directly to patients through Mobile Vision Clinics deployed across 76 cystic fibrosis centers nationwide.

The results:
• 415+ patients received essential eye exams
• More than 50% of patients served were from rural areas
• Wait times were reduced to less than 30 days
• Families reported a 98 NPS score
• Mobile clinics provided a controlled environment designed for vulnerable and immunocompromised patients

By bringing ophthalmic assessments directly to the point of need, the program helped remove access barriers and supported timely initiation of critical CF medication.

One accountable clinical trial partner. Better access. Less patient burden. Timely safety monitoring.

Read the full case study to see how point-of-need ophthalmic care can support post-market safety programs:

https://hubs.ly/Q04vZGyx0

09/01/2026

We’re hiring a Sr. Marketing Manager to join 20/20 Onsite.

This is a hands-on role for a B2B marketer who understands the clinical research ecosystem and wants to own marketing from strategy through ex*****on.

You’ll work across demand generation, ABM, content, HubSpot, reporting, sales enablement, events, and field marketing, with one clear goal: help build qualified pipeline and strengthen 20/20 Onsite’s position as the trusted partner for ophthalmic assessments in clinical trials.

We’re looking for someone who:
• Has 4–6 years of B2B marketing experience within pharma, CROs, clinical research, or trial sites
• Knows how to market complex services to multiple stakeholders
• Is highly comfortable with HubSpot, reporting, analytics, and pipeline attribution
• Can turn technical clinical concepts into clear, credible messaging
• Wants to own programs, execute quickly, and continuously improve what’s working
• Uses AI thoughtfully to make marketing faster and more effective without sacrificing accuracy or quality

This is an opportunity to have a real impact on a growing organization helping sponsors and CROs remove barriers for clinical trial participants and protect critical ocular endpoints.

📍 Everett, MA
💼 Full-time
📈 Strong opportunity to grow with the marketing function

Know someone who would be a great fit? Please share this with them.

Apply here: https://hubs.ly/Q04v-LNH0

08/27/2026

DPHARM 2026 is coming up right in our hometown of Boston and the 20/20 Onsite team will be there in full force!

This year’s conversations around reducing site burden, expanding patient access, simplifying clinical development, and improving trial efficiency are exactly the kinds of challenges we work on every day.

For sponsors and CROs managing trials with ocular requirements, the question is not simply how to complete the assessments. It’s how to do it without creating another operational burden for sites or patients.

That’s where we come in.

Attending from 20/20 Onsite:
• Sonali Bloom, Chief Executive Officer
• Jessica McKenzie, VP, Life Sciences
• Queenly Berko, Business Development Representative
• Sam Larberg, Account Executive
• Katie Sigg, Account Executive
• Keenan Siciliano, Account Executive

If you’re attending DPHARM, let’s connect. DM us to set up a meeting!

08/24/2026

From rare disease and CNS to oncology, immunology, and ophthalmology, sponsors and CROs may need specialized ophthalmic assessments integrated into protocols, sites, workflows, and patient visits.

When those requirements are not planned or executed correctly, the warning signs can include enrollment stalls, screen-fail spikes, referral bottlenecks, slow site activation, and inconsistent data.

In our on-demand webinar, Yes, Your Study is at Risk: Risk Mitigation Plans for Endpoints, Jessica McKenzie shares a practical framework for identifying those risks early and determining the right operational response.

You’ll learn how to:
• Recognize early warning signs that ocular endpoints are at risk
• Add point-of-need ophthalmic capacity when needed
• Align certified staff and validated equipment with existing workflows
• Standardize imaging and certification processes
• Determine when an operational fix is enough, and when a protocol or endpoint redesign may be required

One accountable ophthalmic partner can make a complex requirement much easier to manage.

20/20 Onsite delivers specialized ophthalmic assessments wherever your trial requires them, helping sponsors and CROs protect timelines, data integrity, patient experience, and trial continuity.

Watch the webinar on demand:
https://hubs.ly/Q04tm8cs0

08/19/2026

We’re hiring an Accounting Manager to join the 20/20 Onsite team in Everett, MA.

This is a key role for an experienced accounting professional who wants real ownership in a growing organization. You’ll work closely with our Controller to lead month-end close, own customer invoicing, oversee day-to-day accounting operations, develop processes and controls, and help strengthen the finance function as we continue to scale.

We’re looking for someone who is:
- Experienced in accounting operations and US GAAP
- Comfortable owning the month-end close process
- A strong manager and mentor
- Independent, proactive, and willing to solve problems without waiting for direction
- Excited to improve processes and build greater structure in a growing company

Location: Everett, MA
Full-Time
Base Salary: $115,000–$130,000

At 20/20 Onsite, our work helps pharmaceutical sponsors, CROs, research sites, and trial participants overcome barriers in clinical research through flexible, point-of-need ophthalmic assessment solutions.

If you’re looking for an opportunity where you can own your function, make an impact, and help shape how a growing organization operates, we’d love to hear from you.

Apply today: https://hubs.ly/Q04tmsDM0

08/18/2026

In neurology studies, imaging risks often remain invisible until they begin to affect timelines, budgets, and data quality.

For Clinical Operations teams, the better approach is to identify those risks before they become operational problems.

In our on-demand webinar, Critical Imaging Risks in GLP-1 and Neurology Studies, experts discuss:
• Early warning signs of imaging challenges in active trials
• How preclinical insights can inform protocol development
• Where imaging requirements are expanding across therapeutic areas
• Hidden imaging risks sponsors and CROs may be overlooking
• How earlier planning can protect timelines, patient safety, and ROI

If you’re involved in planning or executing neurology studies, this is a practical conversation worth watching.

Watch the on-demand webinar:
https://hubs.ly/Q04tlZH60

08/13/2026

What if the strongest data in your neurology trial came down to the smallest details?

Neurology studies rely on complex assessments, multiple vendors, and highly specialized personnel. Even small inconsistencies can create downstream risks to trial timelines, endpoints, and regulatory outcomes.

Our latest blog shares proven strategies to strengthen clinical trial data quality in neurology studies, including:
• Standardized workflows and trained, qualified personnel
• Consistent, calibrated equipment across all sites
• Real-time oversight and data review
• Patient-centered approaches that reduce variability

At 20/20 Onsite, quality is built into every assessment. Our data quality performance consistently outperforms industry benchmarks:
• 99% Latest Protocol Accuracy vs. industry averages of 84.7% in Phase I, 70% in Phase II, and 68% in Phase III
• Latest Query Rate: 3.74% vs. industry average of 5–7%
• 98% data accuracy submission rate

Stronger data. Clearer endpoints. Confident outcomes.

Read the full blog to learn how to protect data quality in your neurology trials:
https://hubs.ly/Q04sh1jV0

08/11/2026

What happens when a new FDA requirement adds ophthalmic assessments to an already-active clinical trial regardless of the therapeutic area?

For one biopharmaceutical sponsor running four simultaneous trials, a mid-trial protocol change created an urgent need to implement specialized ophthalmic assessments across 65 sites, without disrupting existing study timelines.

20/20 Onsite was brought in to rapidly deploy protocol-aligned equipment, certified technicians, and standardized processes across the entire study.

The result:
• 65 sites fully operational in just 8 weeks
• 11 participants assessed within the first 60 days
• A typical 90–120 day ramp-up period cut roughly in half
• Protocol-mandated ophthalmic visits completed without participants missing required windows
• Standardized equipment, training, and data collection across all participating sites

This case study shows how the right partner can help sponsors respond quickly to unexpected protocol changes while protecting timelines, data quality, and ocular endpoints.

Read the full case study: https://hubs.ly/Q04shmLR0

08/07/2026

What does it really mean to design a clinical trial around the patient?

Last night, leaders from across the Boston life sciences community came together for A New Lens on Patient-Centric Trial Design, an evening of honest conversation about what patient centricity looks like when it moves beyond intention and becomes part of how a study is designed and delivered.

The discussion explored the many factors that shape a patient’s ability and willingness to participate in a clinical trial, including travel, scheduling, access to specialized assessments, communication, site burden, and the realities of fitting trial participation into everyday life.

One of the clearest takeaways from the evening was that patient centricity cannot simply be added to a protocol after the major decisions have already been made. It needs to be considered early, intentionally, and across the entire trial ecosystem.

That means listening to patients and caregivers.

It means understanding the operational challenges faced by sites.

It means sponsors, CROs, service providers, and clinical teams working together to identify unnecessary burdens before they become barriers to enrollment, retention, and data quality.

We are also incredibly grateful to our panelists:
Beth Marsh, Chief Commercial Officer at Neurotech Pharmaceuticals
Jeffrey Cehelsky, Chief Operating Officer at Trialport
Yesha Raval, Director of Operational Strategy at Lexitas Pharma Services

Each brought a valuable and distinct perspective to the discussion, helping connect patient experience, clinical operations, commercialization, site ex*****on, and trial strategy.

And a big thank-you to our moderator, Sonali Bloom, for guiding such a thoughtful and engaging conversation.

Thank you as well to everyone who attended, asked questions, shared experiences, and continued the conversation throughout the evening. Events like this are valuable because they create space for the clinical research community to step outside of individual roles and organizations and consider what better trial participation can look like for everyone involved.

Thank you to Boston Bio Connections and everyone who helped make the evening possible.

07/20/2026

What could your clinical trial accomplish if qualified participants were ready before site activation?

For one ophthalmic gene therapy trial, 20/20 Onsite developed a mobile pre-screening program that brought protocol-aligned assessments directly to potential participants.

The result:
• 28 of the first 34 enrolled participants (82%) had already been pre-screened and qualified
• Enrollment moved forward without waiting on traditional site activation and scheduling
• Patient travel and screening burden were reduced
• The trial earned FDA Fast Track designation

This case study shows how point-of-need ophthalmic assessments can help sponsors remove enrollment bottlenecks, improve the patient experience, and accelerate critical development timelines.

Read the full case study: https://hubs.ly/Q04p-S5_0

Address

Boston, MA
02110

Website

http://www.2020onsite.com/

Alerts

Be the first to know and let us send you an email when 20/20 Onsite posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your business to be the top-listed Engineering Company in Boston?